Progression of medullary thyroid carcinoma: Assessment with calcitonin and carcinoembryonic antigen doubling times

European Journal of Endocrinology

Volumn 158, Issue 2, 2008, Pages 239-246

  Giraudet, Anne Laure ^a   Al Ghulzan, Abir ^a   Aupérin, Anne ^a   Leboulleux, Sophie ^a   Chehboun, Ahmed ^a   Troalen, Frédéric ^a   Dromain, Clarisse ^a   Lumbroso, Jean ^a   Baudin, Eric ^a   Schlumberger, Martin ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE; KI 67 ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMAGE ANALYSIS; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOLID TUMOR; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME; BLOOD; CARCINOMA; DISEASE COURSE; MIDDLE AGED; THYROID TUMOR; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; THYROID NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 38949129191     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0667     Document Type: Article

References (30)

1. Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli J & Schlumberger M. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. British Journal of Cancer 2003 88 1537-1542.
2. Leboulleux S, Baudin E, Travagli J & Schlumberger M. Medullary thyroid carcinoma. Clinical Endocrinology 2004 61 299-310.
3. Collins V, Loeffler R & Tivey H. Observations on growth rates of human tumors. American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 1956 76 988-1000.
4. Santoro M & Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice, Endocrinology and Metabolism 2006 2 42-52.
5. Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Hartl D, Travagli JP, Baudin E, Bonniaud G & Schlumberger M. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. Journal of Clinical Endocrinology and Metabolism 2007 92 4185-4190.
6. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom A, Christian M & Gwyther S. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of National Cancer Institute 2000 92 205-216.
7. Stepanas A, Samaan N, Hill CJ & Hickey R. Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer 1979 43 825-837.
8. Mendelsohn G, Wells SJ & Baylin S. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer 1984 54 657-662.
9. Cohen R, Campos JM, Salaun C, Heshmati HM, Kraimps JL, Proye C, Sarfati E, Henry JF, Niccoli-Sire P & Modigliani E. Preoperative calcitonin levels are predictive of tumor size and postoperative normalization in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2000 85 919-922.
10. Pyke C, Hay I, Goellner J, Bergstralh E, van Heerden J & Grant C. Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma. Surgery 1991 110 964-970 (discussion 970-961).
11. Barbet J, Campion L, Kraeber-Bodéré F & Chatal J. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2005 90 6077-6084.
12. Busnardo B, Girelli M, Simioni N, Nacamulli D & Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984 53 278-285.
13. Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M & Kumahara Y. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Annals of Surgery 1984 199 461-466.
14. Rougier P, Calmettes C, Laplanche A, Travagli J, Lefevre M, Parmentier C, Milhaud G & Tubiana M. The values of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma. Cancer 1983 51 855-862.
15. Katoh R, Bray C, Suzuki K, Komiyama A, Hemmi A, Kawaoi A, Oyama T, Sugai T & Sasou S. Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Human Pathology 1995 26 139-146.
16. Saltman B, Singh B, Hedvat C, Wreesmann V & Ghossein R. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 2006 140 899-905 (discussion 905-896).
17. Tisell L, Oden A, Muth A, Altiparmak G, Mõlne J, Ahlman H & Nilsson O. The Ki67 index a prognostic marker in medullary thyroid carcinoma. British Journal of Cancer 2003 89 2093-2097.
18. Robbins R, Wan Q, Grewal R, Reibke R, Gonen M, Strauss H, Tuttle R, Drucker W & Larson S. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. Journal of Clinical Endocrinology and Metabolism 2006 91 498-505.
19. Downey R, Akhurst T, Gonen M, Vincent A, Bains M, Larson S & Rusch V. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. Journal of Clinical Oncology 2004 22 3255-3260.
20. Leboulleux S, Schroeder P, Schlumberger M & Ladenson P. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice, Endocrinology and Metabolism 2007 3 112-121.
21. Schwartz D, Rajendran J, Yueh B, Coltrera M, Leblanc M, Eary J & Krohn K. FDG-PET prediction of head and neck squamous cell cancer outcomes. Archives of Otolaryngology - Head and Neck Surgery 2004 130 1361-1367.
22. Vansteenkiste J, Stroobants S, Dupont P, De Leyn P, Verbeken E, Deneffe G, Mortelmans L & Demedts M. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. Journal of Clinical Oncology 1999 17 3201-3206.
23. Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G & Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. Journal of Gastrointestinal Surgery 2003 7 953-959 (discussion 959-960).
24. Adams S, Baum R, Hertel A, Schumm-Dräger P, Usadel K & Hör G. Metabolic (PET) and receptor (SPET) imaging of well- and less well- differentiated tumours: comparison with the expression of the Ki-67 antigen. Nuclear Medicine Communications 1998 19 641-647.
25. Ong S, Schöder H, Patel S, Tabangay-Lim I, Doddamane I, Gönen M, Shaba A, Tuttle R, Shah J & Larson S. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. Journal of Nuclear Medicine 2007 48 501-507.
26. Motté P, Vauzelle P, Gardet P, Chillani P, Caillou B, Parmentier C, Bohuon C & Bellet D. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies. Clinica Chimica Acta 1988 174 35-54.
27. AJCC. Thyroid. In American Joint Committee on Cancer: AJCC Cancer Staging Manual, edn 6, pp 77-87 New York: Springer, 2002.
28. Tollefson M, Slezak J, Leibovich B, Zincke H & Blute M. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clinic Proceedings 2007 82 422-427.
29. Bertolini F, Bengala C, Losi L, Pagano M, lachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, Luppi G & Conte PF. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics 2007 68 1455-1461.
30. de Azambuja E, Cardoso F, de Castro GJ, Colozza M, Mano M, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart M & Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. British Journal of Cancer 2007 96 1504-1513.